tiprankstipranks
Vir Biotechnology price target lowered to $100 from $125 at H.C. Wainwright
The Fly

Vir Biotechnology price target lowered to $100 from $125 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Vir Biotechnology to $100 from $125 and keeps a Buy rating on the shares following the Q4 results. The company has a "chock-full of datasets" and potential to separate from a crowded HBV field as the story moves beyond COVID-19, the analyst tells investors in a research note. The firm says the Phase 2 trial combining VIR-2218 plus interferon is demonstrating robust results so far.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on VIR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles